NMR Spectroscopy-Based Metabolomics Profiling: A Clinically Helpful Approach for Prostate Cancer Early Detection

PCa diagnosis is difficult since there is/are no acceptable, sensitive, and specific tumor biomarkers. The most common cancer in the world to be diagnosed in males over 50 is prostate cancer (PCa). In its early stages, there are no symptoms, and the cancer grows slowly. Measuring a predetermined list of certain metabolites is the goal of metabolomics. Understanding metabolites and their metabolic pathways is essential for finding new biomarkers, and the most significant pattern may have a big impact on how PCa is treated. Due to their low sensitivity and specificity, current non-screening diagnostic techniques have certain limitations when it comes to diagnosing PCa.